CoChat

Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Open access
Zhou, Yu-Hao, Ma, Xiu-Qiang, Wu, Cheng, Lu, Jian, Zhang, Shan-Shan, Guo, Jia, Wu, Shun-Quan, Ye, Xiao-Fei, Xu, Jin-Fang, He, Jia · 2012 · PLoS ONE

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Anti-obesity drugs are widely used to prevent the complications of obesity, however, the effects of anti-obesity drugs on cardiovascular risk factors are unclear at the present time. We carried out a comprehensively systematic review and meta-analysis to assess the effects of anti-obesity drugs on cardiovascular risk factors. METHODOLOGY AND PRINCIPAL FINDINGS: We systematically searched Medline, EmBase, the Cochrane Central Register of Controlled Trials, reference lists of articles and proceedings of major meetings for relevant literatures. We included randomized placebo-controlled trials that reported the effects of anti-obesity drugs on cardiovascular risk factors compared to placebo. Overall, orlistat produced a reduction of 2.39 kg (95%CI-3.34 to -1.45) for weight, a reduction of 0.27 mmol/L (95%CI: -0.36 to -0.17) for total cholesterol, a reduction of 0.21 mmol/L (95%CI: -0.30 to -0.12) for LDL, a reduction of 0.12 mmol/L (95%CI: -0.20 to -0.04) for fasting glucose, 1.85 mmHg reduction (95%CI: -3.30 to -0.40) for SBP, and a reduction of 1.49 mmHg (95%CI: -2.39 to -0.58) for DBP. Sibutramine only showed effects on weight loss and triglycerides reduction with statistical significances. Rimonabant was associated with statistically significant effects on weight loss, SBP reduction and DBP reduction. No other significantly different effects were identified between anti-obesity therapy and placebo. CONCLUSION/SIGNIFICANCE: We identified that anti-obesity therapy was associated with a decrease of weight regardless of the type of the drug. Orlistat and rimonabant could lead to an improvement on cardiovascular risk factors. However, Sibutramine may have a direct effect on cardiovascular risk factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0039062

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram of the literature search and trials selection process.
Figure 1 Flow diagram of the literature search and trials selection process.CC BY · PubMed Central
Figure 2 Mean reduction in weight loss (kg) based on sibutramine and orlistat. CI, confidence intervals; IV, inverse variance.
Figure 2 Mean reduction in weight loss (kg) based on sibutramine and orlistat. CI, confidence intervals; IV, inverse variance.CC BY · PubMed Central
Figure 3 Subgroup analyses for the effects of anti-obesity on cardiovascular risk factors based on the type of drug. CI, confidence intervals; IV, inverse variance.
Figure 3 Subgroup analyses for the effects of anti-obesity on cardiovascular risk factors based on the type of drug. CI, confidence intervals; IV, inverse variance.CC BY · PubMed Central
Figure 4 Summary of the relative risks of all adverse outcomes assessed.
Figure 4 Summary of the relative risks of all adverse outcomes assessed.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 84

Metadata

Authors
Zhou, Y.-H., Ma, X.-Q., Wu, C., Lu, J., Zhang, S.-S., Guo, J., Wu, S.-Q., Ye, X.-F., Xu, J.-F., & He, J.
Affiliations
Second Military Medical University (CN)
Corresponding author
He, Jia
Venue
PLoS ONE
Published
2012-06-20
Volume
7
Issue
6
Pages
e39062
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2163687543
Cited by
84
References
57
Citations by year
2025: 2 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 6 · 2018: 5 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 10 · 2013: 13
FWCI
1.15
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Natural Science Foundation of China
  • Program of Shanghai Subject Chief Scientist
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
anti-obesity drugs, cardiovascular risk factors, orlistat, sibutramine, rimonabant, weight loss, blood pressure, cholesterol, triglycerides, fasting blood glucose, obesity
MeSH terms
Cardiovascular Diseases, Humans, Obesity, Weight Loss, Randomized Controlled Trials as Topic, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1371/journal.pone.0039062
The paper
Zhou, Y.-H., Ma, X.-Q., Wu, C., Lu, J., Zhang, S.-S., Guo, J., Wu, S.-Q., Ye, X.-F., Xu, J.-F., & He, J. (2012). Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE. https://doi.org/10.1371/journal.pone.0039062

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.